The group's total revenue for the period ending September 30 climbed from SEK 784.1 million a year ago to SEK 928.2 million. Zinzino’s core sales markets contributed SEK 917.3 million, while the manufacturing subsidiary Faun Pharma added SEK 10.9 million in external sales. Accumulated revenue for the first nine months of 2026 rose by 21 percent to SEK 2,787.1 million.
In section Releases
Zinzino Reports 18 Percent Revenue Growth in Third Quarter
Gothenburg-based Zinzino Group posted an 18 percent revenue increase for the third quarter of 2026, reaching SEK 928.2 million. The company’s performance was bolstered by a surge in North American sales and continued expansion in South American markets, offsetting softer results in Eastern Europe and the Baltic region.
Regional performance varied significantly throughout the quarter. North America emerged as a primary growth engine, with quarterly revenue jumping 55 percent to SEK 195 million. South America also showed substantial momentum, posting a 189 percent increase, though from a smaller base of SEK 10.1 million. Conversely, East Europe and the Baltics faced headwinds, recording declines of 14 percent and 13 percent respectively. The Nordics remained largely flat, while Central Europe maintained steady growth with a 19 percent uptick.
Comments (0)
No comments yet. Be the first!